Karuna Therapeutics, Inc. (KRTX): Price and Financial Metrics


Karuna Therapeutics, Inc. (KRTX): $107.51

0.88 (+0.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KRTX Stock Price Chart Interactive Chart >

Price chart for KRTX

KRTX Price/Volume Stats

Current price $107.51 52-week high $161.98
Prev. close $106.63 52-week low $92.26
Day low $106.14 Volume 354,237
Day high $112.00 Avg. volume 222,925
50-day MA $118.65 Dividend yield N/A
200-day MA $119.54 Market Cap 3.21B

Karuna Therapeutics, Inc. (KRTX) Company Bio


Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.


KRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

KRTX Latest Social Stream


Loading social stream, please wait...

View Full KRTX Social Stream

Latest KRTX News From Around the Web

Below are the latest news stories about Karuna Therapeutics Inc that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Karuna Therapeutics (KRTX) Presents At Annual SVB Leerink Global Health Conference

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | February 24, 2022

Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update

BOSTON, February 24, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a general business update.

Yahoo | February 24, 2022

Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster

Analysts say company is taking novel approach to treating mental illnesses, Alzheimer's

Yahoo | February 22, 2022

One Karuna Therapeutics, Inc. (NASDAQ:KRTX) insider upped their stake by 2.2% in the previous year

Viewing insider transactions for Karuna Therapeutics, Inc.'s ( NASDAQ:KRTX ) over the last year, we see that insiders...

Yahoo | February 16, 2022

Emerald Mutual Fund Advisers Trust Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA ...

Leola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.

Yahoo | February 2, 2022

Read More 'KRTX' Stories Here

KRTX Price Returns

1-mo -8.86%
3-mo 7.78%
6-mo -17.02%
1-year -6.01%
3-year N/A
5-year N/A
YTD -17.93%
2021 28.95%
2020 34.84%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9687 seconds.